Preclinical and clinical trials of the new tuberculosis drug perchlozon
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and safety of the agent and consider the adverse effec...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2016-03-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/31957/pdf |
| id |
doaj-fb038c632bd145359e573e43d0d89e97 |
|---|---|
| record_format |
Article |
| spelling |
doaj-fb038c632bd145359e573e43d0d89e972020-11-25T03:06:36Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422016-03-0188311111528973Preclinical and clinical trials of the new tuberculosis drug perchlozonP K YablonskiyT I VinogradovaYu N LevashevM V PavlovaE K ZilberA A StarshinovaN V SapozhnikovaI V ChernokhaevaL I ArchakovaN V ZabolotnykhM L VitovskayaThe paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and safety of the agent and consider the adverse effects of its treatment for respiratory TB. The use of perchlozon as a component of combination therapy versus standard chemotherapy regimens significantly reduces abacillation time in pulmonary TB caused by its drug-resistant pathogen. In terms of the higher prevalence of TB induced by its pathogen resistant to many drugs (with multiple and broad-spectrum drug resistance), perchlozon is an essential drug that has antituberculous activity mainly against multidrug-resistant Mycobacterium tuberculosis strains and gives patients with the severest and epidemiologically poor form of TB the chance to recover.https://ter-arkhiv.ru/0040-3660/article/viewFile/31957/pdftuberculosischemotherapyperchlozonpreclinical evaluationclinical efficacyadverse eventsindications for use |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
P K Yablonskiy T I Vinogradova Yu N Levashev M V Pavlova E K Zilber A A Starshinova N V Sapozhnikova I V Chernokhaeva L I Archakova N V Zabolotnykh M L Vitovskaya |
| spellingShingle |
P K Yablonskiy T I Vinogradova Yu N Levashev M V Pavlova E K Zilber A A Starshinova N V Sapozhnikova I V Chernokhaeva L I Archakova N V Zabolotnykh M L Vitovskaya Preclinical and clinical trials of the new tuberculosis drug perchlozon Терапевтический архив tuberculosis chemotherapy perchlozon preclinical evaluation clinical efficacy adverse events indications for use |
| author_facet |
P K Yablonskiy T I Vinogradova Yu N Levashev M V Pavlova E K Zilber A A Starshinova N V Sapozhnikova I V Chernokhaeva L I Archakova N V Zabolotnykh M L Vitovskaya |
| author_sort |
P K Yablonskiy |
| title |
Preclinical and clinical trials of the new tuberculosis drug perchlozon |
| title_short |
Preclinical and clinical trials of the new tuberculosis drug perchlozon |
| title_full |
Preclinical and clinical trials of the new tuberculosis drug perchlozon |
| title_fullStr |
Preclinical and clinical trials of the new tuberculosis drug perchlozon |
| title_full_unstemmed |
Preclinical and clinical trials of the new tuberculosis drug perchlozon |
| title_sort |
preclinical and clinical trials of the new tuberculosis drug perchlozon |
| publisher |
"Consilium Medicum" Publishing house |
| series |
Терапевтический архив |
| issn |
0040-3660 2309-5342 |
| publishDate |
2016-03-01 |
| description |
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and safety of the agent and consider the adverse effects of its treatment for respiratory TB. The use of perchlozon as a component of combination therapy versus standard chemotherapy regimens significantly reduces abacillation time in pulmonary TB caused by its drug-resistant pathogen. In terms of the higher prevalence of TB induced by its pathogen resistant to many drugs (with multiple and broad-spectrum drug resistance), perchlozon is an essential drug that has antituberculous activity mainly against multidrug-resistant Mycobacterium tuberculosis strains and gives patients with the severest and epidemiologically poor form of TB the chance to recover. |
| topic |
tuberculosis chemotherapy perchlozon preclinical evaluation clinical efficacy adverse events indications for use |
| url |
https://ter-arkhiv.ru/0040-3660/article/viewFile/31957/pdf |
| work_keys_str_mv |
AT pkyablonskiy preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT tivinogradova preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT yunlevashev preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT mvpavlova preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT ekzilber preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT aastarshinova preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT nvsapozhnikova preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT ivchernokhaeva preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT liarchakova preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT nvzabolotnykh preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon AT mlvitovskaya preclinicalandclinicaltrialsofthenewtuberculosisdrugperchlozon |
| _version_ |
1724673496135499776 |